Leiden Jeffrey M's Form 4 filing
Odyssey Therapeutics, Inc. (ODTX) · filed May 11, 2026
- Accession no.
- 0001193125-26-217607
- Filed
- May 11, 2026
- Trade date
- May 7-11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 5 derivative transactions. Open-market purchases total $100.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leiden Jeffrey MCIK 0001242825 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | PPurchaseAcquired | +5,000 | $20.00 | +$100,000 | 270,198 | Direct | |
| May 11, 2026 | Common Stock | CConversionAcquired | +28,698 | –F1,F2,F3 | – | 28,698 | Indirect | |
| May 11, 2026 | Common Stock | MOption exerciseAcquired | +2,963 | –F5 | – | 31,661 | Indirect | |
| May 11, 2026 | Common Stock | FTax withholdingDisposed | −17 | $18.00 | −$306 | 31,644 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Common Stock | CConversionDisposed | −8,527 | –F1 | – | 0 | Indirect | |
| May 11, 2026 | Common Stock | CConversionDisposed | −10,291 | –F2 | – | 0 | Indirect | |
| May 11, 2026 | Common Stock | CConversionDisposed | −9,880 | –F3 | – | 0 | Indirect | |
| May 7, 2026 | Common Stock | AGrant or awardAcquired | +626,220 | $0.00 | $0 | 626,220 | Direct | |
| May 11, 2026 | Common Stock | MOption exerciseDisposed | −2,963 | –F5 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F2
The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F3
The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F5
The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.